The TSE brain inocula used in this study, conducted during November 2010–December 2011, were derived from 2 natural L-BSE isolates from France (02-2528 and 08-0074); a lemur injected intracerebrally (i.c.) with the 02-2528 L-BSE cattle isolate (3); and a human patient with MM2-cortical sCJD. Consent was obtained for using tissues from the human patient in research, including genetic analyses. Animal experiments were performed in the biohazard prevention area (A3) of the Anses-Lyon animal facilities, in accordance with the guidelines of the French Ethical Committee (decree 87-848) and European Community Directive 86/609/EEC.

Six-week-old TgOvPrP4 mice and 4-week-old Syrian golden hamsters were injected i.c. with 20 and 30 µL, respectively, of 10% (wt/vol) brain homogenates in 5% sterile glucose. Serial passages were performed in TgOvPrP4 mice by i.c. inoculation of 1% (wt/vol) homogenates from mice positive for protease-resistant PrP (PrP^res). At the terminal stage of the disease, animals were euthanized, and their brains and spleens were collected for PrP^res analyses by Western blot and for histopathologic studies (8).

Figure 1

Figure 1. . . . Susceptibility of Syrian golden hamsters to MM2-cortical subtype sporadic Creutzfeldt-Jakob disease (sCJD) and L-type bovine spongiform encephalopathy (L-BSE) prions. Disease-associated prion protein (PrP^d) was analyzed in brains of...

In hamsters, transmission of the MM2-cortical sCJD agent was inefficient. Clinical signs were absent up to 876 days postinoculation (dpi) (Table), and disease-associated PrP (PrP^d) in brain samples was not detected by paraffin-embedded tissue blot (PET-blot) (Figure 1, panel A), immunohistochemical (Figure 1, panel C), or Western blot (Figure 1, panels E, F) analyses. PrP^res was also undetectable in spleen tissues by Western blot (Table).

In contrast, the L-BSE agent passaged in a lemur was efficiently transmitted to hamsters, with a mean survival period of 529 ± 117 dpi, similar to that for L-BSE from cattle (622 ± 64 dpi) (Table). PET-blot analysis (Figure 1, panel B) showed widespread PrP^res distribution in the brain; immunohistochemical analysis (Figure 1, panel D) showed a granular type of PrP^d deposition that redefined the periphery of most of the blood vessels. Western blot analysis (Figure 1, panels E, F) showed PrP^res in the brains of hamsters inoculated with L-BSE from cattle and lemur and in 1/4 spleens of hamsters injected with L-BSE passaged in lemur (Table). Brain PrP^res was characterized by low apparent molecular mass (≈19 kDa for the unglycosylated band) associated with a lack of reactivity toward the N terminal 12B2 antibody, in contrast to that for the control animal with scrapie (Figure 1, panels E, F).

In TgOvPrP4 mice, all TSEs were efficiently transmitted, as confirmed by PrP^d accumulation in the mouse brains (Table). After serial passages in additional TgOvPrP4 mice, the survival periods in each experiment became considerably shorter (Table; Technical Appendix Figure 1 [PDF - 284 KB - 3 pages]). No statistically significant differences in results were identified between the L-BSE sources (p>0.6). Mean survival period decreased to 111 ± 25 dpi at second passage in mice inoculated with the agent of MM2-cortical subtype sCJD, which differed significantly from that of mice inoculated with L-BSE (p<0.0001). A third passage of both cattle L-BSE and human sCJD did not reduce the survival periods in TgOvPrP4 mice (data not shown).

Figure 2

Figure 2. . . . Western blot molecular typing of protease-resistant prion protein (PrP^res) in brain and spleen tissues of ovine prion protein–transgenic (TgOvPrP4) mice at second passage. PrP^res from mice infected with...

Western blot analyses of PrP^res from mouse brains showed partially similar features for MM2-cortical sCJD and L-BSE, including low molecular mass (≈19 kDa for the unglycosylated band) (Figure 2, panel A) and similar conformational stability of PrP^d after treatment with guanidinium hydrochloride (Technical Appendix Figure 2 [PDF - 284 KB - 3 pages]). However, the proportions of diglycosylated, monoglycosylated, and unglycosylated bands of brain PrP^res differed between sCJD and L-BSE (Figure 2, panel C); higher proportions of diglycosylated PrP^res were found in sCJD-infected mice (mean 67% of the total signal) compared with L-BSE–infected mice (≈18% lower; p<0.0001). PrP^res was readily identified in the spleens of TgOvPrP4 mice at the second passage for sCJD and L-BSE from cattle and at the first passage for L-BSE from lemur (Table). No significant differences in the proportions of PrP^res glycoforms for sCJD-infected versus L-BSE–infected mice were observed in the spleens (Figure 2, panel D), but PrP^res was ≈0.5 kD higher in mice injected with sCJD (Figure 2, panel B, arrows).

Histopathologic analysis showed severe vacuolar lesions in TgOvPrP4 mice infected at second passage with sCJD and lemur-passaged L-BSE (Technical Appendix Figure 3 [PDF - 284 KB - 3 pages]). However, in sCJD-infected mice, vacuolar lesions were mostly observed in the anterior parts of the brain (except the parietal cortex), whereas in mice infected with lemur-passaged L-BSE, the lesions were more widely distributed, involving the colliculi and the hypothalamus. In mice infected with sCJD and lemur-passaged L-BSE, PET-blot analyses showed that most of the PrP^res occurred in the frontal parts of the brain, but the intensity and appearance of PrP^res in the cortex, thalamus, and hippocampus were distinctly different. Immunohistochemical analyses of the hippocampus showed PrP^d deposition in the dentate gyrus in sCJD-infected mice, in contrast to a lack of deposition in lemur-passaged L-BSE–infected mice.

We report the isolation of 2 prion strains derived from L-BSE and MM2-cortical sCJD after transmission in Syrian hamsters and ovine PrP–transgenic mice. In hamsters, we did not transmit any disease with sCJD, but the transmission of L-BSE from lemur was efficient, as previously reported for L-BSE from cattle (7,11). This result suggests that L-BSE did not undergo major modifications after this cross-species transmission and could indicate a clear biologic difference between MM2-cortical sCJD and L-BSE. We also demonstrated the efficient transmission of both L-BSE and MM2-cortical sCJD in TgOvPrP4 mice, which enabled us to compare these diseases in a single model. Unexpectedly, during serial passages, we observed that the agent of MM2-cortical sCJD causes a much more rapidly fatal disease. Despite similar molecular features in sCJD and L-BSE, including the PrP^res electrophoretic mobility and the conformational stability of PrP^d, sCJD and L-BSE differed in PrP^res glycosylation for the mouse brains and gel migrations for the mouse spleens. Mice infected with MM2-cortical sCJD versus those infected with L-BSE also showed distinct lesion profiles and PrP^d distribution, which confirms clear biologic differences between these diseases.

Although only 1 case of sCJD of a unique molecular subtype was examined in our study, our observations do not support the hypothesis of a causal relationship between L-BSE and this human sCJD subtype. Our study thus encourages further investigations using the proposed bioassay approach for a more complete evaluation of possible relationships between L-BSE and human prion diseases.